Wide Ranks

INZY

Inozyme Pharma, Inc.

2.72

Top Statistics
Market Cap 174 M Forward PE -1.74 Revenue Growth 0.00 %
Current Ratio 7.68 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.9090 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 131 M Total Cash Per Share 2.05 Total Debt 46 M
Total Debt To Equity 56.52 Current Ratio 7.68 Book Value Per Share 1.29
All Measures
Short Ratio 1099.00 % Message Board Id finmb_568596329 Shares Short Prior Month 3 M
Return On Equity -0.7942 City Boston Uuid f627b06e-ce15-3126-896c-1db8a4222086
Previous Close 2.65 First Trade Date Epoch Utc 1 B Book Value 1.29
Beta 1.54 Total Debt 46 M Volume 1 M
Price To Book 2.11 Fifty Two Week Low 2.56 Total Cash Per Share 2.05
Shares Short Previous Month Date 1 B Target Median Price 14.50 Max Age 86400
Recommendation Mean 1.33 Sand P52 Week Change 0.3133 Target Mean Price 18.75
Net Income To Common -96494000 Short Percent Of Float 0.0558 Implied Shares Outstanding 64 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 611160
Average Volume10days 611160 Total Cash 131 M Next Fiscal Year End 1 B
Held Percent Insiders 0.0050 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 2.65 Target Low Price 12.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 4.47 Open 2.69
Free Cashflow -55929500 State MA Dividend Yield 0.00 %
Return On Assets -0.3569 Time Zone Short Name EST Trailing Eps -1.55
Day Low 2.58 Address1 321 Summer Street Shares Outstanding 64 M
Price Hint 4 Target High Price 43.00 Website https://www.inozyme.com
52 Week Change -0.2935 Average Volume 297045 Forward Eps -1.62
Recommendation Key strong_buy Compensation As Of Epoch Date 1 B Quick Ratio 717.40 %
Is_sp_500 False Regular Market Day High 2.74 Profit Margins 0.00 %
Debt To Equity 56.52 Fifty Two Week High 7.79 Day High 2.74
Shares Short 3 M Regular Market Open 2.69 Industry Key biotechnology
Earnings Growth 0.00 % Revenue Growth 0.00 % Shares Percent Shares Out 0.0516
Operating Cashflow -91206000 Currency USD Time Zone Full Name America/New_York
Market Cap 174 M Is_nasdaq_100 False Zip 02210
Quote Type EQUITY Industry Biotechnology Long Name Inozyme Pharma, Inc.
Regular Market Day Low 2.58 Held Percent Institutions 0.9667 Current Price 2.72
Address2 Suite 400 Enterprise To Ebitda -0.9090 Financial Currency USD
Current Ratio 7.68 Industry Disp Biotechnology Number Of Analyst Opinions 8
Country United States Float Shares 36 M Two Hundred Day Average 5.04
Enterprise Value 89 M Forward PE -1.74 Regular Market Volume 1 M
Ebitda -98893000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases.

The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.

It has a license agreement with Yale University for specified therapeutic and prophylactic products.

The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.